A guideline-grade improvement to a lab that touches almost every chronic-disease decision in adulthood. The science is settled — every major kidney society has signed on (KDIGO 2024). The action is small: confirm your lab uses the 2021 formula, and at a meaningful decision-point — starting an SGLT2 inhibitor, getting a CT with contrast, a chemo dose, a transplant work-up — ask for cystatin C. The catch is access: not every clinic orders it routinely, and you may need to push.
The kidney's filtering rate — how many millilitres of blood your kidneys clean per minute — is the single number that drives most kidney-related decisions in medicine: who gets a CKD diagnosis, who gets referred to a nephrologist, what dose of chemo or antibiotic is safe, whether swapping table salt for a potassium-based substitute is safe rather than dangerous, who qualifies for a transplant. Measuring it directly is expensive and slow (you get injected with a tracer and your blood is drawn over hours), so almost every clinical decision uses an estimate calculated from a blood test. That estimate is called eGFR.
The standard estimate has used creatinine — a waste product made by skeletal muscle and cleared by the kidneys — since the 1970s. The problem: creatinine is made by muscle. A 60-year-old marathoner and a 60-year-old in a wheelchair with the same actual kidney function will have wildly different creatinine levels, and the formula can't always tell which is which. In 2009, the field's best formula tried to patch this by multiplying the result by 1.159 if the patient was Black, on the theory — never rigorously validated — that Black patients had higher average muscle mass (Delgado et al., AJKD 2022). Race is a social category, not a biological one, and the multiplier had the practical effect of making a Black patient's kidneys look 16% healthier than they were.
Cystatin C is the second marker. It's a small protein made at a near-constant rate by every nucleated cell in your body — not by muscle in particular — and it's filtered out by the kidneys just like creatinine. Because production is roughly the same whether you're frail or jacked, vegan or carnivore, young or old, the level in your blood is a cleaner read of how well your kidneys are filtering (Shlipak et al., JAMA 2022). The combined formula — eGFRcr-cys, which uses both creatinine and cystatin C — gets you closer to the truth than either marker alone.
How big a deal this actually is
When researchers modelled what would happen if every US clinical lab switched to the race-free formula overnight, the numbers were enormous and went in two directions at once. About 434,000 Black adults would be newly identified as having chronic kidney disease they were previously missing; another 584,000 Black adults would be moved into a more severe stage that warrants closer treatment. At the same time, about 5.5 million non-Black adults would be reclassified out of CKD entirely, and another 4.6 million would be downgraded to a milder stage (Diao et al., JAMA 2021). The net is fewer total CKD diagnoses — but the ones that remain are more accurate. Disease that was hidden is now visible; disease that was overstated is now correctly small.
The transplant waitlist is where you can see this most concretely. Until the equation changed, Black patients on the kidney waitlist had their kidney function silently inflated, which kept them off the list longer and lower in priority. A retrospective review of US transplant centres found that 27% of Black candidates were reclassified into a sicker — and therefore higher-priority — CKD stage when the new formula was applied. The Organ Procurement and Transplantation Network responded by mandating that programs retroactively adjust waiting times for affected Black patients. The result: roughly 5.3 more transplants per 1,000 Black candidates (Mohottige et al., JAMA Internal Medicine 2024).
The second piece of evidence is newer and applies to everyone, not only Black patients. When you run both creatinine and cystatin C, the two numbers don't always agree — and the gap itself tells you something. A 2025 meta-analysis from the CKD Prognosis Consortium followed 821,000 outpatients for an average of 11 years. About 11% had a "large negative gap" — meaning their cystatin C number was at least 30% lower than their creatinine number. That group's all-cause death rate was roughly 70% higher than people whose two numbers tracked together (Estrella et al., JAMA 2025). The gap is itself a risk signal, separate from the underlying kidney number.
The guideline-side consensus is unusually clean for a recent biomarker. The NKF-ASN Task Force published its final report the same day the NEJM paper appeared, recommending every US lab switch immediately (Delgado et al., 2022). KDIGO — the international standards body for kidney disease — adopted both recommendations in its 2024 guideline at the highest evidence grade it issues for non-emergency labs (1B): if cystatin C is available, the GFR category should be estimated from the combined formula, not creatinine alone (KDIGO 2024).
Who specifically should care
Two groups, with very different reasons.
Anyone whose body composition is unusual for their height and age. Creatinine is a muscle product, so when muscle mass is low — older adults, anyone frail or recovering from major illness, people with cirrhosis (the liver makes less of the creatinine precursor), amputees, paraplegic patients, people with eating disorder histories, vegetarians with very low protein intake — the creatinine number is artificially low, and the kidney estimate calculated from it is artificially high. The kidneys look fine on paper while they're quietly failing. Roughly 15% of patients with measured GFR under 60 have a perfectly normal serum creatinine (Casal et al., Kidney360 2022) — they have meaningful kidney disease that creatinine alone will not flag.
It works in the other direction too. Bodybuilders, anyone with unusually high muscle mass for their frame, people on high-protein diets, and anyone taking creatine supplements (which raise creatinine directly) often look like they have mild CKD on a routine creatinine eGFR when they don't. Cystatin C settles the question.
Black adults near any clinical decision-point. If you're Black and your most recent creatinine eGFR came back somewhere between 50 and 70, and your lab is still using the 2009 formula, your true kidney number is meaningfully lower than the printout — and the difference matters for whether you start an SGLT2 inhibitor, get referred to a nephrologist, qualify for transplant listing, or get told your blood pressure medication is fine as-is (Delgado et al., AJKD 2022). Confirming the lab uses CKD-EPI 2021 is the first move; adding cystatin C closes the rest of the gap.
For most healthy adults outside these groups, with normal weight, normal muscle, and a creatinine eGFR comfortably above 60, the additional test changes nothing. Skip it.
What continues to happen if nothing changes
For most people, nothing — most adults with healthy kidneys never reach a decision-point where the formula matters. The story below is for the ones who do.
The Black patient on the CKD-3 borderline. Your eGFR has been hovering at 62, then 58, then 60 for years. With the old formula you sit just above the diagnostic line and your primary care doctor calls it "fine, but let's keep an eye on it." With the corrected formula your real number is closer to 50. The five-year version of the difference: you don't get started on an SGLT2 inhibitor when it would have slowed the decline, you don't get the nephrology referral that would have caught the proteinuria early, and when you finally do meet the dialysis criteria a decade later, your spouse is the one helping you with the catheter. The intervention costs about $80. The cost of not doing it is years of independent life.
The grandmother on chemo. She weighs 110 pounds, has lost twenty since the diagnosis, and her creatinine looks normal. The oncologist calculates her carboplatin dose from a creatinine-based GFR that overestimates her true kidney function by perhaps 30%. The first cycle is harder than expected; the second sends her to the emergency department with acute kidney injury; the third has to be delayed, which gives the cancer time. A single cystatin C at the start would have caught the gap. (Casal et al., 2022)
The middle-aged man with the gap. His creatinine eGFR is 75 — reassuringly normal. He doesn't run a cystatin C because nobody suggests it. Four years later he has a cardiac event nobody saw coming. In hindsight his cystatin C had been around 50 the whole time; that discordance was the most actionable cardiovascular risk signal he had, and his medical record never recorded it. The CKD Prognosis Consortium data say his hazard ratio for death was about 1.69 compared to a non-discordant peer of the same age (Estrella et al., 2025) — roughly the difference between a current smoker and a never-smoker.
The pattern: creatinine-only eGFR is fine for the median patient. It is dangerous for the specific patients near decisions where a single number drives a binary action — drug dose, transplant listing, referral, qualifying for a class of medication. Those are the rooms where the better test pays for itself in hours.
How to actually do this
Three short asks, in order. None of them need to be repeat-every-year tasks; this is one-time-at-a-decision-point work.
You don't need to repeat the cystatin C at every visit. Once is usually enough to recalibrate the decision; routine creatinine-based monitoring continues afterward.
When cystatin C also misleads
Cystatin C is cleaner than creatinine, not perfect. Several conditions raise blood cystatin C without any real change in kidney function, which makes your kidneys look worse on the test than they really are (Chen et al., Kidney360 2022):
The general rule: if creatinine and cystatin C disagree, ask which marker has a known confounder operating right now. If the patient is sarcopenic, frail, or cirrhotic, trust the cystatin C. If the patient is on prednisone or in an inflammatory flare, trust the creatinine (or repeat the cystatin C when the flare resolves). When neither has an obvious confounder and the gap is still large, the combined eGFRcr-cys formula is the most accurate answer, and an unexplained gap is itself the prognostic finding (Estrella et al., 2025).
What gets repeated and is wrong
"Removing race from the formula harms Black patients by overestimating their kidney disease." The opposite. At the population level the change reveals real disease that was hidden, accelerates qualifying medications, and shortens transplant waits — the 27% reclassification of Black transplant candidates into higher-priority CKD stages produced about 5.3 more transplants per 1,000 candidates, not fewer (Mohottige et al., 2024). There is one legitimate edge — living-donor evaluation, where the new formula may disqualify some willing Black donors with truly normal kidneys (the formula wasn't designed for the donor decision). For everyone not being evaluated as a donor, the change is the unambiguous gain.
"Cystatin C is better, so it replaces creatinine." No. The combined formula outperforms either marker alone. KDIGO 2024 recommends using both together when cystatin C is available — not substituting one for the other (KDIGO 2024). The two markers have different non-kidney confounders, so the agreement between them is the signal.
"My creatinine is normal so my kidneys are fine." About 15% of patients with measured GFR under 60 — actual kidney disease by any reasonable definition — have a perfectly normal serum creatinine (Casal et al., 2022). Mostly older, mostly thinner, mostly women. The reassurance from a normal creatinine alone is conditional on having a typical body for your age.
"This is settled, so my lab already uses it." Maybe. Maybe not. CAP-accredited labs in the US largely moved by 2023, but the cutover was not uniform, and some integrated health systems were still showing the 2009 formula in mid-2024. The fastest check is to open your last eGFR result and read the printed formula name. Don't assume.
What changes when you do this
Within a week of the blood draw, the kidney number on your chart is the most accurate one you've ever had. For most readers nothing visible happens; the value of an accurate number is mostly latent, paid out in decisions that never go wrong.
For the patient who turns out to have hidden CKD — the sarcopenic 70-year-old whose creatinine was lying about her, the Black patient whose 2009-formula number had been falsely reassuring — the next clinic visit looks different. There's a nephrology referral on the chart. The blood pressure medication gets reviewed. If diabetes is in the picture, an SGLT2 inhibitor goes on the medication list; if there's significant protein in the urine, a RAS-inhibitor dose gets nudged up. Caught this early — stage G1 to G3a, before symptoms — those first ninety days of management are where the trajectory actually bends. None of these feel dramatic in the moment. The version of the story where you skip them ends with dialysis a decade earlier than necessary.
For the patient about to take a kidney-stressing drug — chemotherapy, certain antibiotics, contrast for a CT — the dose is calibrated to a true number instead of a flattering one. The visible payoff is the AKI that doesn't happen, the cycle that isn't delayed, the readmission that doesn't occur. None of those events are notable when they don't happen. They are catastrophic when they do (Davis et al., Radiology 2020).
For the rare patient with a large discordance between the two markers and no obvious confounder, the gap itself becomes a flagged cardiovascular risk factor — the kind a cardiologist now has to engage with, rather than discover after the event (Estrella et al., 2025).
And at the population level, the kind of patient who would have been the last person on the transplant list moves up; the kind of patient who would have been silently misclassified gets named. The medicine still has to be paid for and the procedures still have to happen, but the queue is finally honest.
Adjacent things worth knowing
eGFR is only half of the modern kidney check. The other half is the urine albumin-to-creatinine ratio (uACR) — how much protein your kidneys are leaking. CKD staging uses both, and a normal eGFR with elevated uACR is still kidney disease. If you're going for a confirmatory cystatin C, ask for a spot urine ACR in the same visit.
The conversation about race in clinical algorithms didn't stop at kidney function — pulmonary function tests, certain cardiovascular risk calculators, and the obstetric VBAC predictor have all gone through similar reckonings on different timelines. The pattern is the same: a "race adjustment" that turned out to be a stand-in for variables nobody had measured directly.
Kidney donor evaluation is a special case the 2021 formula was not built for. If you're considering donating a kidney, the work-up uses a measured GFR — not an estimate — for exactly the reasons that motivate this entry.
- — This is the number that stages early kidney disease — get it right and you catch CKD in the window that matters.
- — Your eGFR feeds straight into the PREVENT heart-risk score; a race-free, cystatin-C reading keeps that estimate honest.
- — Creatine supplements inflate the creatinine your eGFR is built on; cystatin C reads through the artefact.
- — Knowing your eGFR matters before swapping to a potassium salt — low kidney function turns a heart-healthy swap risky.
- — Same lesson, different lab: a single standard number can mislead in specific people. Know when your eGFR, like your HbA1c, needs a second marker.
- — A reassuring eGFR can hide real disease — exactly the 'normal isn't the same as fine' problem.
- — Like the race-based kidney formula, the pulse oximeter carries a built-in bias by skin tone — a sibling story in how tools fail quietly.
- — Just as diabetes is screened in the eye each year, the kidney gets watched with eGFR and cystatin C.
- — Same skill on a different organ: knowing what your kidney numbers actually mean and their limits.
Substance + claimed effects
The entry covers two related shifts in how a clinical lab reports kidney function: (1) the 2021 race-free CKD-EPI creatinine equation (Inker et al., NEJM 2021), which removed the race coefficient from the previous 2009 CKD-EPI equation, and (2) the parallel push to use cystatin C (alone or combined with creatinine, eGFRcr-cys) as a confirmatory marker. Both were endorsed jointly by the NKF-ASN Task Force in September 2021 (Delgado et al., AJKD 2022) and elevated to a global 1B recommendation in KDIGO 2024. Claimed consequences: (a) more accurate CKD classification, especially in Black adults and in patients with non-typical body composition (sarcopenia, cirrhosis, amputees, the very frail); (b) better-calibrated drug dosing for renally cleared medications (chemotherapy, SGLT2 inhibitors, anticoagulants, contrast); (c) earlier eligibility for kidney transplant listing and nephrology referral in Black patients; (d) discordance between cystatin C- and creatinine-based eGFR (eGFRdiff) as an independent prognostic marker for cardiovascular and all-cause mortality. The article addresses all four consequences holistically.
Evidence by addressing question
mechanism — why creatinine misleads and cystatin C corrects
Mechanism. Serum creatinine is produced from creatine phosphate breakdown in skeletal muscle and excreted by glomerular filtration plus a modest amount of tubular secretion. Its blood level therefore reflects both kidney filtration and muscle mass / dietary protein. Cystatin C is a 13-kDa cysteine-protease inhibitor produced at a near-constant rate by all nucleated cells, freely filtered at the glomerulus, and metabolised in the proximal tubule — meaning its serum level depends much less on muscle mass, sex, age, or diet (Chen et al., Kidney360 2022; Shlipak, Inker, Coresh, JAMA 2022).
Science — origin of the 1.159 race coefficient. The 2009 CKD-EPI creatinine equation multiplied eGFR by 1.159 if the patient self-identified as Black, derived from a small fitting cohort in which Black participants had slightly higher mean serum creatinine at any given measured GFR. The biologic narrative ("Black people have more muscle mass") was never validated outside the fitting cohort and is now widely understood to confound race with body composition, diet, and access to care. The 2021 refit dropped that coefficient entirely (Inker et al., NEJM 2021; Delgado et al., 2022).
Science — accuracy. In the development/validation cohorts (Inker 2021), the P30 (% of estimates within 30% of measured GFR by iothalamate or iohexol clearance) was approximately 86–87% for the 2021 race-free creatinine equation (similar to the 2009 equation for non-Blacks but more accurate for Blacks when integrated across populations), and ~92% for the combined creatinine–cystatin C (eGFRcr-cys) equation. The eGFRcr-cys equation also minimised between-race differences in CKD prevalence estimates relative to either single-marker equation (Inker et al., 2021).
evidence — reclassification at population scale
Science. Modelling on NHANES projected that swapping the 2009 race-adjusted equation for the 2021 race-free creatinine equation would (a) newly classify ~434,000 Black US adults as having CKD and reclassify ~584,000 Black adults to a more severe stage, and (b) "un-diagnose" ~5.51 million non-Black adults and downgrade another ~4.59 million to less severe stages (Diao et al., JAMA 2021). The net direction is fewer total CKD diagnoses but better-targeted ones.
Science — discordance and prognosis. The CKD Prognosis Consortium (CKD-PC) meta-analysis of 821,327 outpatients found that 11% had a "large negative" eGFRdiff (eGFRcys ≥30% lower than eGFRcr). Over 11-year follow-up, that group had hazard ratios of 1.69 for all-cause mortality, 1.61 for cardiovascular mortality, 1.54 for heart failure, and 1.29 for kidney-failure-with-replacement-therapy relative to non-discordant participants. Among inpatients, 35% had large negative eGFRdiff (Estrella et al., JAMA 2025).
Practice / guideline. The NKF-ASN Task Force (2021) recommended (1) immediate adoption of the 2021 CKD-EPI creatinine equation by all US labs, (2) national effort to expand cystatin C availability and use it confirmatorily, (3) further research into novel filtration markers (Delgado et al., 2022). KDIGO 2024 escalated this with Recommendation 1.1.2.1 (grade 1B): "If cystatin C is available, the GFR category should be estimated from the combination of creatinine and cystatin C (eGFRcr-cys)" (KDIGO 2024).
audience — who benefits most from cystatin C confirmation
Practice. Cystatin C is most informative when the creatinine signal is known to be unreliable. Established indications include: sarcopenia, frailty, low body weight, malnutrition, cirrhosis (where reduced hepatic creatine synthesis lowers serum creatinine independently of kidney function), limb amputation, paraplegia, eating disorders, very high muscle mass (bodybuilders), and pre-decision moments where misclassification has high cost — kidney donor evaluation, narrow-therapeutic-index drug dosing, transplant candidacy, oncology dose calculation (Chen et al., 2022; Shlipak et al., 2022; Casal et al., 2022). The 2024 KDIGO recommendation effectively widens this to "anyone at risk for CKD where the lab has cystatin C available" (KDIGO 2024).
Practice — equity. Black Americans bear 3.8× the population CKD prevalence of White Americans and historically waited about twice as long for transplant listing; the 2021 equation change measurably narrowed both gaps. A retrospective analysis of the kidney transplant waitlist found that 27% of Black candidates were reclassified upward in CKD severity, and the OPTN mandated retrospective waiting-time adjustments — translating to roughly 5.3 additional transplants per 1,000 Black candidates (Mohottige et al., JAMA Internal Medicine 2024).
protocol — what the reader actually does
Practice. Three operational steps: (1) confirm that the reporting lab uses the "CKD-EPI 2021" race-free creatinine equation rather than the legacy 2009 race-adjusted one. As of mid-2024, >80% of US clinical laboratories had migrated; the CAP and AMP issued an implementation guidance in 2021 and reinforced it in 2022. (2) Request a serum cystatin C (often paired with creatinine and reported as eGFRcr-cys; Quest test code 94588, LabCorp test code 121265). Self-pay range $50–$130 for the bundled test; insurance coverage exists under medical-necessity criteria including any of the KDIGO confirmatory scenarios. (3) If eGFRcr and eGFRcys disagree by >15 mL/min/1.73m² (or eGFRcys is ≥30% lower than eGFRcr), interpret with the cystatin C value if no inflammatory/thyroid/steroid confounder is present, and treat the discordance itself as a cardiovascular risk signal (KDIGO 2024; Estrella et al., 2025; Chen et al., 2022).
contraindications — when cystatin C also misleads
Science. Non-GFR determinants of serum cystatin C include systemic inflammation (acute illness, autoimmune flares), active hyperthyroidism (raises cystatin C) and untreated hypothyroidism (lowers it), exogenous glucocorticoid use, obesity, smoking, and rapid changes in body composition. These factors generally bias cystatin C upward, leading to underestimation of true GFR — the opposite direction from creatinine bias in sarcopenia. The magnitude is smaller than creatinine's non-GFR bias in muscle-disorder states, but it matters in patients on prednisone or in active inflammatory flares (Chen et al., 2022). One additional limitation: cystatin C has no analogous "24-hour urinary excretion" cross-check (creatinine clearance), so an unexpected value cannot be re-litigated against a urine sample.
misconceptions — what most coverage gets wrong
Three recurring errors: (a) "removing race from the equation harms Black patients by overestimating their CKD." The opposite is true at population level — the 2021 equation reveals previously masked disease and accelerates therapy in Black patients; the legitimate concern is narrow (living donor screening — see §3e). (b) "Cystatin C is a better test than creatinine, so it replaces it." It is a complementary marker; the combined eGFRcr-cys outperforms either alone, and KDIGO recommends both, not substitution (KDIGO 2024). (c) "If my creatinine-eGFR is normal, my kidneys are fine." Roughly 15% of patients with measured GFR <60 have a normal serum creatinine, mostly because of low muscle mass; cystatin C is the way to detect this (Casal et al., 2022).
practicalities — cost, access, lab workflow
Practice. Cystatin C assays are standardised against the international reference material ERM-DA471/IFCC (since 2010), so values are portable across major US reference labs. Direct-to-consumer pricing for the bundled "Cystatin C with eGFR" test ranges from ~$56 (Ulta Lab Tests via Quest) to ~$120 (LabCorp via LifeExtension); insurance-billed pricing is variable but Medicare has a Local Coverage Determination (L37618) covering medically necessary indications. Turnaround 2–5 business days. The legacy 2009 race-adjusted creatinine equation has been removed from the OPTN kidney allocation calculator and from most major EHR vendors' default GFR display; verifying the lab's equation version is a one-time check (Delgado et al., 2022).
stakes — what continues if nothing changes
Felt-experience forecast. A patient relying on creatinine-only eGFR with the legacy 2009 equation (still in use at some labs through 2024) experiences three downstream effects over years: (1) for Black patients near the CKD-3 threshold, delayed nephrology referral, delayed RAS-inhibitor and SGLT2-inhibitor initiation, delayed transplant listing — translating to faster progression to dialysis and excess cardiovascular events (Diao et al., 2021; Mohottige et al., 2024); (2) for sarcopenic, frail, or cirrhotic patients with falsely-reassuring creatinine, chemotherapy and contrast doses calibrated to overestimated GFR — manifesting as nephrotoxicity, hospital readmissions, and AKI events; (3) for the 11% of outpatients with discordant eGFRcr-cys, hidden CV risk that single-marker testing cannot surface — the 1.69x mortality hazard documented by CKD-PC (Estrella et al., 2025).
payoff — what changes when the reader requests it
Felt-experience forecast. A patient who confirms their lab uses the 2021 equation and adds cystatin C once at a decision-point gains: accurate CKD staging (sometimes "un-diagnosis" of mild CKD where creatinine alone falsely flagged it; sometimes earlier diagnosis where creatinine missed it); right-sized chemotherapy and contrast doses; defensible drug-dosing decisions for narrow-therapeutic-window medications; and the prognostic signal of eGFRdiff itself, which can prompt CV risk stratification independent of any single GFR number (KDIGO 2024; Estrella et al., 2025). Onset latency: the lab result is back in 2–5 days; clinical consequences (changed therapy, transplant listing) follow within weeks; population-level mortality benefit accrues over years.
out-of-scope — what this entry does not cover
Albuminuria (the second pillar of CKD staging — eGFR is the "G" axis, urine albumin-creatinine ratio is the "A" axis), the specific dialysis or transplant management pathway, the broader debate over race in non-renal clinical algorithms (pulmonary function tests, VBAC calculators, the 2020 ABG-correction equations), and pediatric eGFR (which uses the separate Schwartz / U25 equations).
The credibility range
Optimist case. The 2021 race-free equation plus routine cystatin C confirmation is a rare structural intervention: better science, better equity, better drug safety, all at once. The race coefficient was never biologically justified — even its originators acknowledged it was a fitted artifact of a small cohort. Removing it both corrects bias and dignifies the principle that race is not a biological variable. Adding cystatin C closes the residual ~6–8 percentage-point P30 gap between race-free creatinine eGFR and measured GFR, and the combined eGFRcr-cys is genuinely the most accurate non-invasive kidney function estimate available outside of formal iohexol clearance studies. The CKD-PC discordance data adds a second independent benefit: eGFRdiff is itself a prognostic biomarker for CV mortality, on the order of a known major risk factor (Estrella et al., 2025). KDIGO 2024 endorsing this as a 1B recommendation — strong, moderate-quality — is unusual for an emerging biomarker; the evidence base genuinely cleared the bar.
Skeptic case. The 2021 equation is still imperfect: among living kidney donor candidates, the new equation reclassifies 17.7% of Black donors as having pre-donation CKD and 25.5% as post-donation CKD, which has the unintended effect of disqualifying willing Black donors and potentially shrinking the Black living-donor pool. Cystatin C, for all its advantages, is non-trivially affected by inflammation, obesity, thyroid status, and corticosteroid exposure — common confounders in the very patients (cancer, autoimmune disease, transplant recipients) where it is most often ordered. The KDOQI commentary noted that timely access to cystatin C is still patchy in US practice, and the test adds cost (~$50–$130) without universal insurance coverage. The 27% Black-patient transplant-listing benefit is real but modest relative to the structural inequities in dialysis access that the equation change did not touch. And the equity framing risks obscuring that race-free eGFR also "un-diagnoses" 5.5M non-Black adults whose mild CKD was a real flag — for them the change is a downgrade in surveillance.
Author's call. The evidence base for the 2021 equation as the default is strong and the field is aligned (KDIGO 1B, NKF-ASN endorsement, AMA/CAP/AACC implementation guidance, OPTN adoption). The author's call lands optimist on the equation switch — this is settled science, and labs still using the 2009 equation in 2026 are out of step with guidelines. On cystatin C, the call is more nuanced: routine confirmation at every CKD-relevant decision-point is the KDIGO ideal but reality lags; the practical recommendation for readers is to request cystatin C once at a decision-point (drug dosing, transplant evaluation, near-threshold CKD diagnosis, suspected sarcopenia/cirrhosis), not as a quarterly addition to every basic metabolic panel. controversy: 2 — not contested in expert opinion, but with one real edge (donor reclassification) and one access edge (cystatin C availability).
Stakeholder + incentive map
- Drivers of adoption: NKF, ASN, KDIGO, KDOQI (professional bodies); CAP and AACC (laboratory standards); OPTN (transplant equity); major academic nephrology centres (Tufts, UCSF, Johns Hopkins, Penn). Aligned on both the equation change and cystatin C expansion.
- Drivers of cystatin C uptake: Cystatin C reagent vendors (Siemens, Roche, Gentian, Abbott) — small but real commercial interest. Notably modest — cystatin C revenue is a fraction of creatinine-test revenue.
- Counter-incentives: A minority of nephrologists and clinical chemists who argued for retaining race or proposed alternative variables (e.g., "kidney function biomarkers index" or muscle-mass-adjusted approaches). The "retain race" position lost the academic argument by 2022. Living-donor advocacy groups raised concern about donor disqualification.
- Health-system friction: EHR vendors had to update GFR display; some legacy systems were slow. Reference labs had to rebuild reporting formats. Implementation lag was the main barrier, not philosophical disagreement.
Population variability
- Black adults: Largest individual-level benefit from the equation change — earlier diagnosis, earlier referral, earlier transplant listing (Mohottige et al., 2024). Living donor candidates are the partial exception (Diao et al., 2021).
- Sarcopenic / frail / elderly: Largest individual-level benefit from cystatin C addition. The creatinine-based number routinely overestimates GFR in this group; cystatin C corrects (Chen et al., 2022).
- Patients with cirrhosis: Hepatic creatine synthesis is reduced, lowering serum creatinine independent of GFR; cystatin C is preferred for accurate staging and for hepatorenal syndrome assessment.
- Athletes / very high muscle mass: Creatinine overestimates muscle-driven baseline; cystatin C corrects.
- Vegetarians / very low protein intake: Lower creatinine production; cystatin C corrects.
- Patients on systemic corticosteroids, with active hyperthyroidism, or with severe systemic inflammation: Cystatin C biased upward; eGFRcr may be more reliable in these contexts.
- Pediatric: Out of scope; uses Schwartz or U25 equations.
- Pregnancy: Both markers are unreliable; measured GFR or 24-h creatinine clearance preferred.
Knowledge gaps
- Living donor evaluation needs its own validated equation set; the 2021 refit was not designed for donor-candidate decisions, and the 17.7% reclassification rate in Black donor candidates is an open problem (Diao et al., 2021).
- Frequency of cystatin C re-testing in stable CKD is not established — once is well-supported, quarterly is not.
- eGFRdiff as a treatment target is unstudied: does narrowing the discordance (e.g., by treating inflammation) improve outcomes, or is it purely a marker?
- Novel markers (β-trace protein, β2-microglobulin, panel-based approaches) may further improve accuracy; the NKF-ASN Task Force explicitly called for funding in this area (Delgado et al., 2022).
- Global standardisation of cystatin C assays is good but not perfect; some non-standardised legacy assays remain in lower-resource settings.
Scope vs. brief. The brief named four consequences: CKD classification, drug dosing, equity in kidney care, and the role of cystatin C. The article covers all four end-to-end. The classification piece lives in evidence and audience; drug dosing in stakes, protocol, and payoff; equity threads through evidence, audience, misconceptions, and payoff; cystatin C is woven through every section as the partner story to the equation change. Treating these as one entry — not two — was a deliberate call: the 2021 equation and the cystatin C recommendation were issued in the same Task Force report and live or die together in practice.
Hard scoping calls.
- Albuminuria / urine ACR is the natural companion to eGFR for full CKD staging. Kept it as a brief pointer in
out-of-scoperather than a section — adding it would have doubled the article and the brief did not name it. Future link candidate: a dedicated uACR and CKD staging entry. - Living-donor evaluation is named in the
misconceptionssection as a legitimate edge of the 2021 equation, then deferred. The full donor work-up uses measured GFR (iohexol/iothalamate), which is a different topic entirely. - The broader "race in clinical algorithms" debate (pulmonary function, VBAC, cardiac calculators) is named in
out-of-scopeonly. Each warrants its own entry; treating them here would dilute the kidney-specific action. - Pediatric eGFR (Schwartz, U25) is out — different equation set, different population.
- Pregnancy is out — both markers are unreliable; the work-up is a measured GFR.
Rating difficulties.
longevity: 3was the hardest call. The intervention's mortality benefit accrues to subpopulations near decision-thresholds, not the median adult. A 4 would overstate the population-wide gain; a 2 would understate the magnitude for the patients who do benefit (the JAMA 2025 HR of 1.69 for eGFRdiff-discordant patients is on the order of smoking). Landed at 3 with the call that the entry's audience is heavily weighted toward people considering kidney-affecting decisions.controversy: 2reflects that the equation change itself is settled — but the living-donor reclassification and patchy cystatin C access are real edges. A 1 would have hidden those; a 3 would have overstated the genuine consensus on the equation switch.health_short_term: 2rather than 3 because the felt-experience improvement isn't a daily wellness lift — it's a precision improvement on a clinical decision the reader probably wouldn't notice unless something went wrong.- Considered scoring
moodnon-zero for the dignity / equity dimension (being correctly classified rather than systematically miscounted) but decided that's not a felt-mood effect at the individual level, and inventing one would dilute the score's meaning.
Future-link candidates (entries that would make this one stronger when they exist):
- SGLT2 inhibitors — the highest-volume drug class whose initiation depends on accurate eGFR
- Urine ACR and the second axis of CKD staging
- Kidney transplant evaluation and the OPTN waiting-time correction
- Carboplatin and renally-dosed chemotherapy
- The broader "race in clinical algorithms" pattern (spirometry race correction, the 2020 ABG corrections)
Separate-entry candidates surfaced during the write: living-donor kidney evaluation (the 2021 equation doesn't generalise; deserves its own page); contrast-induced AKI prophylaxis (separate decision tree, separate threshold biology).
Voice notes. Tried hard to keep the "Black patient" framing concrete and unhedged in audience and stakes, since equity-flavoured content has a tendency to slide into abstract policy voice. The "grandmother on chemo" and "middle-aged man with the gap" vignettes in stakes are designed to keep the substance-level consequences felt rather than statistical.
Race-Free eGFR and Cystatin C
A one-time blood test, roughly $50–$130 if insurance won't cover it. Cheap relative to what it changes.
One conversation with your doctor and one extra blood draw. No habit to keep up.
Landmark study in the world's top medical journal, endorsed by every major kidney society. The science is settled.
A more accurate kidney number means earlier treatment for the people who actually have kidney trouble — and fewer wasted years on dialysis later.
If you're on chemo, getting contrast for a scan, or starting a new kidney-affecting drug, this test gets your dose right and avoids a preventable AKI.